Back to Search
Start Over
Induction-related cost of patients with acute myeloid leukaemia in France.
- Source :
-
International journal of clinical pharmacy [Int J Clin Pharm] 2011 Apr; Vol. 33 (2), pp. 191-9. Date of Electronic Publication: 2011 Jan 28. - Publication Year :
- 2011
-
Abstract
- Objective: The economic profile of acute myeloid leukaemia (AML) is badly known. The few studies published on this disease are now relatively old and include small numbers of patients. The purpose of this retrospective study was to evaluate the induction-related cost of 500 patients included in the AML 2001 trial, and to determine the explanatory factors of cost.<br />Setting: "Induction" patient's hospital stay from admission for "induction" to discharge after induction.<br />Method: The study was performed from the French Public Health insurance perspective, restrictive to hospital institution costs. The average management of a hospital stay for "induction" was evaluated according to the analytical accounting of Besançon University Teaching Hospital and the French public Diagnosis-Related Group database. Multiple linear regression was used to search for explanatory factors.<br />Main Outcome Measure: Only direct medical costs were included: treatment and hospitalisation.<br />Results: Mean induction-related direct medical cost was estimated at €41,852 ± 6,037, with a mean length of hospital stay estimated at 36.2 ± 10.7 days. After adjustment for age, sex and performance status, only two explanatory factors were found: an additional induction course and salvage course increased induction-related cost by 38% (± 4) and 15% (± 1) respectively, in comparison to one induction. These explanatory factors were associated with a significant increase in the mean length of hospital stay: 45.8 ± 11.6 days for 2 inductions and 38.5 ± 15.5 if the patient had a salvage course, in comparison to 32.9 ± 7.7 for one induction (P < 10⁻⁴). This result is robust and was confirmed by sensitivity analysis.<br />Conclusion: Consideration of economic constraints in health care is now a reality. Only the control of length of hospital stay may lead to a decrease in induction-related cost for patients with AML.
- Subjects :
- Adolescent
Adult
Chi-Square Distribution
Clinical Trials as Topic economics
Clinical Trials, Phase III as Topic economics
Costs and Cost Analysis
Drug Costs
Female
France
Humans
Length of Stay economics
Linear Models
Male
Middle Aged
Models, Economic
Multicenter Studies as Topic economics
National Health Programs economics
Patient Admission economics
Patient Discharge economics
Retrospective Studies
Salvage Therapy economics
Time Factors
Treatment Outcome
Young Adult
Antineoplastic Combined Chemotherapy Protocols economics
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Hospital Costs
Hospitalization economics
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute economics
Subjects
Details
- Language :
- English
- ISSN :
- 2210-7711
- Volume :
- 33
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- International journal of clinical pharmacy
- Publication Type :
- Academic Journal
- Accession number :
- 21744189
- Full Text :
- https://doi.org/10.1007/s11096-010-9462-1